Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01477762 · ClinicalTrials.gov registry record · NA
Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 165
- Enrollment target
NCT01477762 is a NA study that has completed, run by Emory University. The registered enrollment target is 165 participants.
The verdict
NCT01477762, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 165 participants
- Enrollment target
Study Summary
Posttraumatic stress disorder (PTSD) occurs in some people after exposure to events that cause extreme fear or helplessness. The incidence of war zones worldwide and the prevalence of violence in large cities in the U.S., increases the likelihood that people will experience a traumatizing event in their lifetime. About 1 in 10 people who survive such events will develop PTSD, while most people will get better over time. This suggests that some people may have biological vulnerabilities that make it harder for them to recover. One of these biological risk factors may be related to how stress hormones work in people who get sick. Another is how people react to things that make them afraid or nervous, investigators have found that PTSD patients have higher than normal fear reactions. The part of the brain that reacts to fearful stimulation is linked to stress hormones; the purpose of this study is to examine how these systems interact. The study will suppress stress hormones (cortisol) production in one group of participants, while another will get a placebo. When their cortisol is suppressed, the participants will undergo a startle study to see if their fear responses are decreased. Investigators expect that people PTSD will show a normal fear response when their cortisol levels are reduced, similar to people without PTSD. This research can help discover new medicines for people with PTSD.
Interventions
- DRUG Placebo
- DRUG Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01477762
The ClinicalTrials.gov registry entry for NCT01477762 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01477762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01477762 about?
NCT01477762 is a clinical study titled "Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)". Posttraumatic stress disorder (PTSD) occurs in some people after exposure to events that cause extreme fear or helplessness. The incidence of war zones worldwide and the prevalence of violence in large cities in the U.S., increases the likelihood that people will experience a traumatizing event in t...
What is the current status of trial NCT01477762?
This trial is currently completed. It is a NA study. The enrollment target is 165 participants. The study started on 2011-11. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01477762?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01477762?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.